Maxim Group Lowers Price Target for Lucid Diagnostics After Q1 Results

Lucid Diagnostics (LUCD) reported first-quarter results showing $1.3 million in revenue and a significant net loss, leading Maxim Group to reduce its price target from $3 to $2 while maintaining a Buy rating. The company is awaiting Medicare coverage determination for EsoGuard testing.

By Laiba Immad Tue, June 2, 2026 at 4:57 PM GMT+3 2 min read · Yahoo Finance · June 2, 2026, 13:57 UTC

Maxim Group Lowers Price Target for Lucid Diagnostics After Q1 Results

Topics: penny stock Q1 results stock price target reduction

Read the full article at Yahoo Finance

More World news

Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC
Suburban Propane Reports Fiscal 2026 Results with Increased Adjusted EBITDA and RNG Growth Motley Fool · November 12, 2026, 17:40 UTC
Altimmune Reports Third Quarter 2026 Financial Results Amid Increased R&D Spending Motley Fool · November 12, 2026, 17:40 UTC
CorMedix Reports Q3 2026 Results Amid DefenCath Pricing Transition and Heron Therapeutics Acquisition Plans Motley Fool · November 12, 2026, 17:40 UTC
NUGL Reports Third Quarter Net Income of $0.19 Million and Revenue of $1.04 Million Seeking Alpha · November 12, 2026, 17:38 UTC
Allstate Announces Quarterly Dividend of $1.08 Per Share PR Newswire · November 12, 2026, 17:38 UTC
Stephanie Link Shifts AI Allocation from Nvidia to Micron Technology Following CEO Resignation CNBC · November 12, 2026, 17:37 UTC
Boyd Group Reports 28% Revenue Growth and $90 Million in Cost Savings for Q3 2026 Motley Fool · November 12, 2026, 17:33 UTC
Hugging Face CEO Reaffirms Commitment to Open-Source AI Following Nvidia CEO Jensen Huang's Departure TechCrunch · November 12, 2026, 17:36 UTC
Marimed Reports Record $44.2M Quarterly Revenue and Targets 2027 New York Launch Seeking Alpha · November 12, 2026, 17:30 UTC